alexa Biologics Versus Biosimilars: Are They Similar Molecules? Do They Share Similar Drug Safety Profile?
ISSN: 2167-0870

Journal of Clinical Trials
Open Access

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Share This Page

Additional Info

Loading
Loading Please wait..
 

8th Global Pharmacovigilance & Drug Safety Summit
JULY 06-07, 2017 KUALA LUMPUR, MALAYSIA

Nipom Deka
Amgen Holdings Inc., China
Keynote: J Clin Trial
DOI: 10.4172/2167-0870-C1-015
Abstract
Biologics are medicines made from living cells through highly complex manufacturing processes. Biologics are important treatments for a number of cancers or chronic diseases. Biosimilars are highly similar to an already approved biologic molecule with differences (may be minor) in clinically inactive components. As biologics differ from small-molecule drugs due to their size and complexity, multifaceted manufacturing process, and their potential for immunogenicity, biosimilars cannot be considered "generic versions" of currently approved biologics. Although comparative studies are needed to generate substantive evidence in terms of quality, safety and efficacy, stringent pharmacovigilance procedures are required to detect potential differences in safety signals between biosimilars and their reference products. Unlike small molecule generics, a biosimilar approval requires clinical studies to ensure that small manufacturing changes have not altered the therapeutic efficacy of the biological drug. Post-marketing pharmacovigilance becomes even more critical in case of biosimilars as there is limited information available regarding them. Additionally, the effect of such biosimilars on diverse patient populations with respect to the dosage and duration of therapy needs to be closely monitored. Due to these reasons, biosimilars are required to undergo same pharmacovigilance regulations as its reference product. In my presentation, I would like to present before the audience the risks that the biosimilars could potentially bring in terms of immunogenicity and interchangeability of small molecules compared to the innovator’s biologic molecule. Since biosimilars are many times cheaper than innovator’s biologic molecules, we should not be discouraged in developing biosimilars but should be cautious with its characteristics and requires thorough evaluations. This would ultimately help the needy patient population.
Biography

Nipom Deka is a Physician with 7 years of valuable experience in various departments of Medicine, Surgery, Accident & Emergency and Orthopedics in India & abroad. In 2007, he started his career in Pharmaceutical Industry as a Clinical Investigator for a Phase II trial. Eventually, he moved into Pharmacovigilance joining as a Pharmacovigilance Physician. Over a period of time, he had the opportunity to lead and manage teams of Medical Reviewers & Drug Safety Associates (DSA). Besides working on streamlining & process improvement initiatives, he was actively involved in delivering training on Pharmacovigilance to DSA’s & Physicians in various Organizations, he has been associated with. He was also involved in setting up of Pharmacovigilance units in various country offices in Asia, Africa & Middle East for multiple pharmaceutical companies. Having worked in Pharmacovigilance for more than 10 years, he has gained experience in areas including signal detection, benefit-risk assessment, risk management plan and various process improvement initiatives. In his current role in Amgen, he is providing leadership to the Pharmacovigilance teams in various affiliate offices in Asia Pacific region. As a member of Strategic Leadership Team, he contributes to develop and maintain compliant safety systems working closely with cross functions.

Email: [email protected]

image PDF   |   image HTML
 

Relevant Topics

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri, Food, Aqua and Veterinary Science Journals

Dr. Krish

[email protected]

1-702-714-7001 Extn: 9040

Clinical and Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

[email protected]

1-702-714-7001Extn: 9042

Chemical Engineering and Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001 Extn: 9040

Earth & Environmental Sciences

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

General Science and Health care Journals

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics and Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001 Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Informatics Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Material Sciences Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Mathematics and Physics Journals

Jim Willison

[email protected]

1-702-714-7001 Extn: 9042

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001 Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

John Behannon

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001 Extn: 9042

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords